CA2848065A1 - Method of treating mucoepidermoid carcinoma - Google Patents

Method of treating mucoepidermoid carcinoma Download PDF

Info

Publication number
CA2848065A1
CA2848065A1 CA2848065A CA2848065A CA2848065A1 CA 2848065 A1 CA2848065 A1 CA 2848065A1 CA 2848065 A CA2848065 A CA 2848065A CA 2848065 A CA2848065 A CA 2848065A CA 2848065 A1 CA2848065 A1 CA 2848065A1
Authority
CA
Canada
Prior art keywords
unsubstituted
compound
substituted
formula
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2848065A
Other languages
English (en)
French (fr)
Inventor
James D. Griffin
Lizi WU
Jie Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA2848065A1 publication Critical patent/CA2848065A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2848065A 2011-09-30 2012-09-27 Method of treating mucoepidermoid carcinoma Abandoned CA2848065A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161541758P 2011-09-30 2011-09-30
US61/541,758 2011-09-30
US201261660377P 2012-06-15 2012-06-15
US61/660,377 2012-06-15
PCT/US2012/057480 WO2013049300A1 (en) 2011-09-30 2012-09-27 Method of treating mucoepidermoid carcinoma

Publications (1)

Publication Number Publication Date
CA2848065A1 true CA2848065A1 (en) 2013-04-04

Family

ID=47016842

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2848065A Abandoned CA2848065A1 (en) 2011-09-30 2012-09-27 Method of treating mucoepidermoid carcinoma

Country Status (12)

Country Link
US (1) US20140243396A1 (OSRAM)
EP (1) EP2760445A1 (OSRAM)
JP (1) JP2014532057A (OSRAM)
KR (1) KR20140069038A (OSRAM)
CN (1) CN103906515A (OSRAM)
AU (1) AU2012316020A1 (OSRAM)
BR (1) BR112014005730A2 (OSRAM)
CA (1) CA2848065A1 (OSRAM)
EA (1) EA201490725A1 (OSRAM)
IN (1) IN2014CN02315A (OSRAM)
MX (1) MX2014003873A (OSRAM)
WO (1) WO2013049300A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180058659A (ko) 2015-05-20 2018-06-01 노파르티스 아게 에베롤리무스와 닥톨리십의 약제학적 병용물
TW201825090A (zh) 2016-11-23 2018-07-16 瑞士商諾華公司 增強免疫反應之方法
WO2019107576A1 (ja) * 2017-11-30 2019-06-06 国立大学法人京都大学 始原生殖細胞／始原生殖細胞様細胞の維持増幅及び分化誘導方法
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
CN108578016B (zh) 2018-04-26 2020-09-08 赛诺医疗科学技术股份有限公司 一种经心尖植入式二尖瓣瓣膜装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604629A1 (en) 2005-04-11 2006-10-19 The Trustees Of Columbia University In The City Of New York Methods for treating mild cognitive impairment
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
UA98473C2 (ru) * 2006-11-20 2012-05-25 Новартіс Аг СОЛИ И КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 2-МЕТИЛ-2-[4-(3-МЕТИЛ-2-ОКСО-8-ХИНОЛИН-3-ИЛ-2,3-ДИГИДРОИМИДАЗО[4,5-с]ХИНОЛИН-1-ИЛ)ФЕНИЛ]ПРОПИОНИТРИЛА
WO2009052467A1 (en) * 2007-10-19 2009-04-23 Board Of Regents Of The University Of Texas System Methods of identifying pi-3-kinase inhibitor resistance
US20090192220A1 (en) * 2007-11-19 2009-07-30 Ore Pharmaceuticals Inc. Treatment for solid tumors
WO2009155659A1 (en) * 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
JP2014503500A (ja) * 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択

Also Published As

Publication number Publication date
US20140243396A1 (en) 2014-08-28
EA201490725A1 (ru) 2014-11-28
IN2014CN02315A (OSRAM) 2015-06-19
MX2014003873A (es) 2014-05-28
KR20140069038A (ko) 2014-06-09
BR112014005730A2 (pt) 2017-03-28
AU2012316020A1 (en) 2013-05-09
EP2760445A1 (en) 2014-08-06
CN103906515A (zh) 2014-07-02
JP2014532057A (ja) 2014-12-04
WO2013049300A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
US11130758B2 (en) Tetrahydropyrazolopyrimidine compounds
US8642602B2 (en) Method of inhibiting fibrogenesis and treating fibrotic disease
AU2008251467B2 (en) Methods of treatment of skin ulcers
JP6441947B2 (ja) キノリンを基にしたキナーゼ阻害剤
US20140243396A1 (en) Method of treating mucoepidermoid carcinoma
JP2009513494A (ja) Ｐｄｅ１０阻害剤としてのピロロジヒドロイソキノリン
CN111566106B (zh) 作为cdk抑制剂的化合物
EA034868B1 (ru) Пиридазиноновые соединения и их применение
JP6243539B2 (ja) アリールエーテルをベースとするキナーゼ阻害剤
US20220023381A1 (en) Vdac inhibitors for treating autoimmune diseases
KR20220132592A (ko) 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
KR20220132590A (ko) 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
Felicetti et al. New anti-ovarian cancer quinolone derivatives acting by modulating microRNA processing machinery
JP2023527281A (ja) 神経炎症の処置のためのｃｋ２阻害剤として使用するための、例えばフラボンなどのクロメン－４－オン誘導体
KR20220132589A (ko) 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
KR20240155293A (ko) 고체 형태의 (s)-1-((2',6-비스(디플루오로메틸)-[2,4'-바이피리딘]-5-일)옥시)-2,4-디메틸펜탄-2-아민 및 이의 염
US20090137631A1 (en) Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
US20190055553A1 (en) Methods for identifying and targeting non-coding rna scaffolds
WO2021222350A1 (en) Methods of use for single molecule compounds providing multi-target inhibition to treat covid-19
JP7558187B2 (ja) 貧血の処置におけるムスカリン性アセチルコリン受容体サブタイプ４アンタゴニスト
CN118420692B (zh) 4'-氟代-1,2,3-三氮唑核苷类似物及其制备方法和作为抗狂犬病毒抑制剂的用途
KR20230056824A (ko) Pak4 저해제 및 그의 용도
WO2018157069A1 (en) Treatment of chronic hpv infection with the pan cdk inhibitor dinaciclib
HK1184154A1 (zh) 作为dna-pk抑制剂的咪唑并[4，5-c]喹啉类化合物
AU2014200542A1 (en) Methods of treatment and prevention of neurodegenerative diseases and disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140306

FZDE Discontinued

Effective date: 20160928